Clinical Research Directory
Browse clinical research sites, groups, and studies.
REDUCER Trial (TXA in Urethroplasty)
Sponsor: Amjad Alwaal, MD, MSc, FRCSC, FACS
Summary
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Official title: Reduction of Perioperative Blood Loss in Urethral Reconstruction Using Tranexamic Acid (REDUCER Trial): A Multicenter Pragmatic Randomized Study
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-05-01
Completion Date
2027-03-30
Last Updated
2026-03-30
Healthy Volunteers
No
Conditions
Interventions
Tranexamic Acid
Tranexamic acid (TXA) will be administered perioperatively according to institutional protocol to reduce intraoperative and postoperative bleeding.
Urethroplasty
Surgical urethral reconstruction performed according to standard institutional techniques.
Locations (1)
University Hospital
Newark, New Jersey, United States